Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

NCT ID: NCT04250311

Last Updated: 2023-08-18

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE3
• Total Enrollment: 314 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-12
• Study Completion Date: 2024-12-31

Brief Summary

The main purpose of this study is:

• to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.

Detailed Description

Design: a multicenter, placebo-controlled, double-blind, randomized clinical trial in parallel groups.

The study will include both male and female patients aged 18-64 years with clinical signs of influenza within the first 24 hours of the onset of illness.

The influenza diagnosis must be supported by a positive rapid test (detection of influenza virus antigens in nasal epithelial cells). After the patients provide signed Participant Information Sheet and Informed Consent form, their medical history and body temperature will be recorded and physical examination and rapid diagnostic test performed. Patients who test positive will be assessed for 7 influenza-associated symptoms: cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, fatigue.

4-point Flu Symptom Severity scale will be used: 0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom.

Nasopharyngeal swabs will be obtained from these patients for subsequent real-time reverse transcription polymerase chain reaction (RT-PCR) influenza A/B testing and laboratory tests performed.

If a patient meets all inclusion criteria and does not meet any of the exclusion criteria at Visit 1 (Day 1), he/she will be randomized into one of the treatment groups: Group 1: ММН-407 for 5 days, or Group 2: Placebo on the ММН-407 regimen for 5 days.

The patients will use electronic patient diaries to daily record their morning and evening axillary temperature (taken using a Geratherm mercury-free thermometer) and severity of 7 influenza-associated symptoms (using the Flu Symptom Severity scale). In addition to this, the patients will record doses of antipyretic drugs taken (when applicable) and any worsening of their health status (when applicable, to assess treatment safety and collect adverse events data).

In total, patients will be observed for 14 days (screening and randomization - up to 24 hours, treatment - 5 days, subsequent observation - up to 2 days; and a follow-up 'telephone' visit - Day 14).

During the study, 3 visits from patient to the physician's office and a follow-up telephone visit will be accomplished: 1) patient visits - Days 1, 3 and 7 (Visits 1, 2, and 3) at the medical centre; 2) telephone visit from the physician (Visit 4) - Day 14.

During Visits 2 and 3, the physician will perform a physical examination, record the changes in patients' symptoms and the use of concomitant medications and check the completion of patient diaries. At Visit 2, nasopharyngeal swabs for RT-PCR will be collected. Visit 3 will involve an assessment of treatment compliance and laboratory tests. The telephone visit is intended to provide information on a patient's health status, presence/absence of secondary bacterial complications and the use of antibiotics.

During the study, subjects will be allowed to use symptomatic therapy and medications for their co-morbidities, except for the medicines listed in the "Prohibited Concomitant Medications" section.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

MMH-407

Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

Group Type: EXPERIMENTAL

MMH-407

Intervention Type: DRUG

MMH-407: For oral use.

Placebo

Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo: For oral use.

Interventions

MMH-407

MMH-407: For oral use.

Intervention Type: DRUG

Placebo

Placebo: For oral use.

Intervention Type: DRUG

Other Intervention Names

Raphamin

Eligibility Criteria

Inclusion Criteria

1. Patients of male and female gender aged 18 to 64 years.

2. Uncomplicated, moderate influenza supported by all the symptoms:

• axillary temperature ≥38.1°С on physician examination;
• at least one moderate general symptom of influenza infection (headache, fever/chill, aches in the muscles/joints, weakness/drowsiness);
• at least one moderate respiratory symptom of influenza infection (cough, sore throat, or nasal congestion).

3. Positive influenza rapid test (detection of virus antigens in the nasal epithelium).

4. First 24 hours of the onset of illness.

5. Patients who agree to use a reliable method of birth control during the study.

6. Patients who have provided signed Participant Information Sheet and Informed Consent form to participate in a clinical trial.

Exclusion Criteria

1. Severe influenza infection that requires hospitalization.

2. Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) that requires the use of antibiotics, starting from the first day of illness.

3. Suspected early manifestations of a condition that, on its first onset, produces symptoms similar to those of influenza (other infectious diseases and/or influenza-like syndrome associated with the first onset of a systemic connective tissue disorder or another condition).

4. Patients who require the use of antivirals that are not permitted during the study.

5. Current season influenza vaccination.

6. Prior history or diagnosis of primary or secondary immunodeficiency

7. Patients with any known or suspected malignant neoplasm.

8. An exacerbated or decompensated chronic disease interfering with the subject's participation in the clinical trial.

9. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency), and/or galactosemia.

10. Current allergy to or intolerance of the active substances or any of the excipients in the medications used in the treatment.

11. Pregnancy, breast-feeding, childbirth within less than 3 months prior to the inclusion in the trial, or unwillingness to use contraceptive methods during the study

12. Prior history of non-adherence to medication; mental disorder; or alcohol or substance abuse, which, in the investigator's opinion, will compromise compliance with study procedures.

13. Use of any of the "Prohibited Concomitant Medications" within 2 weeks prior to study entry.

14. Patients who, as judged by the investigator, will fail or be unwilling to comply with the observation requirements or adhere to the dosing regimen during the study.

15. Participation in other clinical studies within 3 months prior to the inclusion in this study.

16. Patients who are related to any of the on-site research personnel directly involved in the conduct of the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).

17. Patients who work for OOO "NPF "Materia Medica Holding" (i.e. company employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Materia Medica Holding

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology

Barnaul, Moscow, Russia

City Hospital # 5

Barnaul, , Russia

Belgorod State National Research University, Hospital Therapy Department

Belgorod, , Russia

Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways

Chelyabinsk, , Russia

City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic

Izhevsk, , Russia

Kazan State Medical University, Internal Medicine Department

Kazan', , Russia

Kuban State Medical University, Infectious Diseases and Phthisiopulmonology Department

Krasnodar, , Russia

Central Clinical Hospital of the Russian Academy of Sciences

Moscow, , Russia

City Clinical Hospital # 10 of the Kanavinsky District of Nizhny Novgorod

Nizhny Novgorod, , Russia

Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways

Nizhny Novgorod, , Russia

Vvedensky City Clinical Hospital

Saint Petersburg, , Russia

City Polyclinic # 25 of the Nevsky District

Saint Petersburg, , Russia

Medical Center "Reavita Med SPb"

Saint Petersburg, , Russia

Llc "Medical Clinic"

Saint Petersburg, , Russia

City Polyclinic # 43

Saint Petersburg, , Russia

Samara City Hospital # 4

Samara, , Russia

Scientific Medical Center for General Therapy and Pharmacology

Stavropol, , Russia

Tver State Medical University, Department of Hospital Therapy

Tver', , Russia

Bashkir State Medical University, Internal Medicine Department

Ufa, , Russia

Volgograd State Medical University

Volgograd, , Russia

Countries

Russia

Other Identifiers

MMH-407-002

Identifier Type: -

Identifier Source: org_study_id